ABP Overview

Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Wall Street analysts forecast ABP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ABPRO Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

ABPRO Holdings Inc. EPS for the last quarter amounts to -0.63 USD, decreased -49.19

ABPRO Holdings Inc (ABP) has 6 emplpoyees as of March 21 2026.

Today ABP has the market capitalization of 0.00 USD.